Table 2 TNF inhibitor (TNFi) treatment in patients with and without fibromyalgia
Total number of patients | Fibromyalgia+ | Fibromyalgia- | P | |
|---|---|---|---|---|
(n = 196) | (n = 42) | (n = 154) | ||
Patients who received at least one TNFi | 141 (71.9 %) | 33 (78.6 %) | 108 (70.1 %) | 0.28 |
Number of TNFi treatments | 1.84 (1.0) | 2.36 (1.1) | 1.68 (0.9) | <0.01 |
Switchers* | 9 (6.5 %) | 5 (15.2 %) | 4 (3.8 %) | 0.03 |
First TNFi | ||||
Mean duration of first TNFi treatment, years | 3.0 (3.8) | 1.7 (2.4) | 3.5 (4.0) | <0.01 |
Reason for TNFi discontinuation: | ||||
Inefficacy % | 54 (69.2 %) | 12 (54.6 %) | 42 (75.0 %) | 0.14 |
Toxicity % | 4 (5.1 %) | 2 (9.1 %) | 2 (3.6 %) | 0.76 |
Inefficacy + toxicity % | 4 (5.1 %) | 3 (13.6 %) | 1 (1.8 %) | 0.23 |
Others % | 16 (20.5 %) | 5 (22.7 %) | 11 (19.6 %) | 1.00 |